Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 8Gastrointestinal 6Other hematologic neoplasm 4Tumor-Agnostic 3Gynecologic 2Breast 2Sarcoma 1Other solid neoplasm 1Myeloid 1Lymphoid 1

Conditions

Immune-related Adverse Event 1

Interventions

Cisplatin 60Carboplatin 55Cyclophosphamide 47Pemetrexed 45Irinotecan 33pembrolizumab 32Paclitaxel 29Etoposide 29Gemcitabine 28Nivolumab 24Bevacizumab 24Interviews as Topic 23Vincristine 22Capecitabine 22Topotecan 20Filgrastim 20Early Intervention, Educational 20fludarabine 19Oxaliplatin 19Docetaxel 19Specimen Handling 18Drug Therapy 18Temozolomide 17Sorafenib 17Leucovorin 17Everolimus 17Educational Status 17Radiotherapy 16Methods 16Fluorouracil 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Antineoplastic Agents × Other solid neoplasm × Clear all
NCT06702566 2024-11-25

The Effect of Serum Ferritin in irAE

Tianjin Medical University Cancer Institute and Hospital

Phase NA Recruiting
1,500 enrolled
Other hematologic neoplasmOther solid neoplasm

Immune-related Adverse Event

Data powered by HemOnc (CC BY 4.0) Colophon âš¡